NIAID TB Drug Screening Program Completes Compound Testing
Data for approximately 340,000 small molecules, including 214,000 compounds screened by the NIH Roadmap Molecular Libraries Screening Centers Network (MLSCN) are scheduled for public release in 2009. The first dataset from the MLSCN screen has been released to PubChem. The Tuberculosis Antimicrobial Acquisition and Coordinating Facility web site will post notification of the release of additional datasets, and these data will also be available through PubChem.
Compounds were tested for their ability to inhibit growth of M. tuberculosis H37Rv under BSL3 containment. The release will include primary testing data and follow up to determine the MIC and cytotoxicity of compounds identified by single dose testing. Selected compounds identified as growth inhibitors with minimal cytotoxicity and good medicinal chemistry properties were identified and represent a valuable resource for mode of action testing and preclinical development. Researchers interested in finding out more about the MLSCN and data should contact Dr. Robert Goldman, NIAID Respiratory Diseases Branch TB Drug Development Program Officer, rgoldman@niaid.nih.gov.
Government Links
Non-Government Links
-
Tuberculosis Antimicrobial Acquisition and Coordinating Facility
http://www.taacf.org/ (non-Government link)